The first studies on the implication of SDH mutations in cancer showed that patients with hereditary paragangliomas and pheochromocytomas, two rare neuroendocrine neoplasms, displayed inactivating mutations of subunits of SDH enzymes [105, 106]. This evidence concerns the gene SDHB and pheochromocytoma.